Values of selected variables.

<p>Values of selected variables.</p

Correlations between muscle activation, kinematics and functional status in children with DMD.

<p>Correlations between muscle activation, kinematics and functional status in children with DMD.</p

Subject characteristics.

<p>Subject characteristics.</p

Global index of muscle activity (Ker-EGI and global EMG-PS) and index of muscle activity for each muscle for the whole gait cycle, stance phase and swing phase (EMG-PS).

<p>Global index of muscle activity (Ker-EGI and global EMG-PS) and index of muscle activity for each muscle for the whole gait cycle, stance phase and swing phase (EMG-PS).</p

Illustration of co-activation index (CI) calculation.

<p>The percentage of the gait cycle is presented on the X-axis (0: heel strike, 100: the following ipsilateral heel strike) and the normalized amplitude of EMG activity on the Y-axis (0–1). Lines represent the mean linear envelope of muscle 1 activation. Dashed lines represent the mean linear envelope of muscle 2 activation. Black color represent muscle activation in the control group. Blue color represent muscle activation in one child with DMD. The calculation index involved overlapping the linear envelopes of muscle 1 and muscle 2, calculating the area of overlap and dividing by the number of data points. Areas of coactivation are represented in grey (control group) and in blue (DMD patient).</p

Electrophysiologic assessment of SMA type 2 and 3 patients.

<p>Electrophysiologic assessment of SMA type 2 and 3 patients.</p

Baseline clinical and physical characteristics and of enrolled patients.

<p>Baseline clinical and physical characteristics and of enrolled patients.</p

Pulmonary function in SMA type 2 and 3 patients.

<p>Pulmonary function in SMA type 2 and 3 patients.</p

Muscle MRI imaging of SMA type 2 and 3 patients.

<p>Muscle MRI imaging of SMA type 2 and 3 patients.</p

Molecular SMA biomarkers.

<p>Molecular SMA biomarkers.</p